These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 3708672)

  • 1. [The effect of long-term hypolipemic treatment with bezafibrate on the lithogenesis of bile in persons with endogenous hypertriglyceridemia].
    Hrabák P; Zák A; Zeman M; Skorepa J; Hrubant K
    Cas Lek Cesk; 1986 May; 125(21):651-4. PubMed ID: 3708672
    [No Abstract]   [Full Text] [Related]  

  • 2. [Comparison of the hypolipemic effects of bezafibrate and fenofibrate in patients with hyperlipoproteinemia type II and IV].
    Sznajderman M
    Przegl Lek; 1984; 41(7):493-9. PubMed ID: 6390536
    [No Abstract]   [Full Text] [Related]  

  • 3. [Effective long-term treatment of primary hyperlipoproteinemias with bezafibrate].
    Schiffl H; Weidmann P; Fragiacomo C; Noseda G; Bachmann C
    Schweiz Med Wochenschr; 1985 Jun; 115(26):907-11. PubMed ID: 3927481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Antilipemic effect of bezafibrate in patients with hyperlipoproteinemia type IV].
    Chwistecki K; Mrukowicz M; Kopel E
    Wiad Lek; 1985 Apr; 38(7):490-4. PubMed ID: 4013323
    [No Abstract]   [Full Text] [Related]  

  • 5. [Effectiveness of bezafibrate in ambulatory treatment of hyperlipidemia].
    Bartnikowska E; Michajlik A; Wegrzyn B
    Pol Tyg Lek; 1983 Sep; 38(39):1219-21. PubMed ID: 6371736
    [No Abstract]   [Full Text] [Related]  

  • 6. [Effect of bezafibrate on lipid and apoprotein levels in patients with idiopathic hypertriglyceridemia].
    Naruszewicz M; Nowicka G; Szostak WB; Kłosiewicz-Latoszek L
    Kardiol Pol; 1982; 25(7-8):527-31. PubMed ID: 7169740
    [No Abstract]   [Full Text] [Related]  

  • 7. [Increase in the fibrinolytic activity in patients with hyperlipoproteinemias type IV treated with bezafibrate].
    Obispo TM; García Fradé LJ; García Avelló A; César J; Sastre A; Navarro JL
    Rev Clin Esp; 1988 Feb; 182(3):151-4. PubMed ID: 3368592
    [No Abstract]   [Full Text] [Related]  

  • 8. [Antilipemic effect of bezafibrate in patients with hyperlipoproteinemia type IIB and IV].
    Chwistecki K; Mrukowicz M; Kopel E
    Przegl Lek; 1984; 41(9):581-6. PubMed ID: 6393227
    [No Abstract]   [Full Text] [Related]  

  • 9. [Effect of bezafibrate on serum lipid, lipoprotein and apoprotein B levels in patients with type II and IV hyperlipoproteinemia].
    Sznajderman M
    Pol Arch Med Wewn; 1983; 70(5-6):259-69. PubMed ID: 6677890
    [No Abstract]   [Full Text] [Related]  

  • 10. [Bile lipid composition in subjects with blood lipid disorders (types II and IV). Effect of a new hypolipemic drug (Etofibrate)].
    Altomonte L; Mingrone G; Ghirlanda G; Manna R; Rebuzzi A; Pala MA; Greco AV
    Minerva Med; 1980 Feb; 71(4):273-8. PubMed ID: 7354946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cholelithiasis and endogenous hypertriglyceridemia in a thirteen year old girl (a case report).
    Rais N; Undre AR; Shah A
    J Postgrad Med; 1991 Oct; 37(4):231-2, 232A. PubMed ID: 1841977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of bezafibrate on the high-density lipoprotein subfractions HDL2 and HDL3 in primary hyperlipoproteinemia type IV.
    Schwandt P; Weisweiler P
    Artery; 1980; 7(6):464-70. PubMed ID: 7236016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biliary lipids, lithogenic index and biliary drug concentrations during etofibrate and bezafibrate treatment.
    Raedsch R; Plachky J; Wolf N; Simonis G
    Eur J Drug Metab Pharmacokinet; 1995; 20(2):113-8. PubMed ID: 8582435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy of bezafibrate and fenofibrate on elevated blood lipids in HLP type IIa, IIb and IV].
    Schwartzkopff W; Luley C; Scheffler W; Lehmann-Leo W; Schilling A; Wegscheider K
    Med Welt; 1982 Apr; 33(17):631-7. PubMed ID: 7098826
    [No Abstract]   [Full Text] [Related]  

  • 15. [Bile lipid change investigation in cholelithiasis (author's transl)].
    Hrabák P; Skorepa J; Dosková M; Novotný L; Konecný K; Zák A; Zeman M
    Cas Lek Cesk; 1975 Aug; 114(34-35):1054-9. PubMed ID: 1175194
    [No Abstract]   [Full Text] [Related]  

  • 16. [Lipid metabolism in patients with cholelithiasis].
    Vasilenko AIu; Lisevitskaia LI; Frolova LM; Parfent'eva EP; Skul'te IV
    Klin Med (Mosk); 1987 Aug; 65(8):65-8. PubMed ID: 3682736
    [No Abstract]   [Full Text] [Related]  

  • 17. Relationship of bile acid pool size to biliary lipid excretion and the formation of lithogenic bile in man.
    Swell L; Bell CC; Vlahcevic ZR
    Gastroenterology; 1971 Nov; 61(5):716-22. PubMed ID: 5117636
    [No Abstract]   [Full Text] [Related]  

  • 18. [The therapeutic efficacy of bezafibrate in hyperlipoproteinemias of various types].
    Noseda G; Fragiacomo C; Weidmann P; Bachmann C
    Schweiz Med Wochenschr; 1980 Dec; 110(49):1875-7. PubMed ID: 7455660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biliary lipid metabolism in gallstone disease and during gallstone dissolution treatment.
    Nilsell K
    Acta Chir Scand Suppl; 1985; 528():1-38. PubMed ID: 3866449
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical experience with bezafibrate.
    Schubotz R; Schneider J; Hausmann L; Mühlfellner G; Mühlfellner O; Kaffarnik H
    Artery; 1980; 8(6):553-9. PubMed ID: 7259534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.